1. Cummings JL. Depression in Parkinson’s disease. Am J Psychiatry 1992; 149: 443–54.
2. Смулевич А.Б. Клиника и систематика депрессий у соматически больных. РМЖ. 1998; 2: 10–5.
3. APA. Diagnostic and Statistical Manual of Mental Disorders (IV-TR), 4th ed. Washington, DC, 2000.
4. Lemke M, Raethjen J. Depression and Parkinson’s disease – pathophysiology, diagnosis, treatment. Bremen: UNI-MED, 2007.
5. Oertel WH, Hoglinger GU, Caraceni T et al. Depression in Parkinson’s disease. Adv Neurol 2001; 86: 373–83.
6. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 1998; 49: 341–61.
7. Голубев В.Л. Депрессия и паркинсонизм. М.: 2000; с. 1–3.
8. Hillen M, Sage JI. Nonvoter fluctuations in patients with Parkinson’s disease. Neurology 1996; 47: 1180–3.
9. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nervy Mental Dis 1990; 178: 27–31.
10. Aarsland D, Larsen JP, Karlsen K et al. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866–74.
11. Lemke MR, Brecht HM, Koester J et al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexile. J Neuropsychiatry Clin Nuerosci 2005; 17: 214–20.
12. Szegedi A, Hillert A, Wetzel H et al. Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clinical Neuropharmac 1997; 20: 536–45.
13. Corrigan MN, Denahan AQ, Wright CE et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11 (2): 58–65.
14. Perugi G, Toni C, Frare F et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001; 34 (4): 137–41.
15. Ostow M. Pramipexole for depression. Am S Psychiatry 2002; 159 (2): 320–1.
16. Reichmann H, Brecht HM, Koster J еt al. Pramipexole in routine clinical practice: a prospective observation trail in Parkinson’s disease. CNS Drugs 2003; 17: 965–73.
17. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s Disease: a national multicentre prospective randomized study. Europ J Neurol 2003; 10: 399–406.
18. Goldberg JF, Burdik KE, Endick CJ et al. Preliminary randomized, double-blind, placebo-controlled trail of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564–6.
19. Zarate CA, Payne JL, Singh J. Pramipexole for bipolar II depression: placebo-controlled proof of concept. Biol Psychiatry 2004; 56: 53–60.
20. Moller JC, Oertel WH, Koster J et al. Long-term efficacy and safety of Pramipexole in advanced Parkinson’s disease: results from a European multicenter trail. Mov Disord 2005; 20 (5): 602–10.
21. Barone P, Scarzella I, Marconi R et al. Depression/Parkinson. Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel group randomized study. J Neurol 2006; 253: 601–17.
22. Ribot TH. The Psychology of Emotions. London, 1897.
23. Assogna F, Cravello L, Caltagirone C, Spalletta G. Anhedonia in Parkinson’s disease: A Systematic Review of the literature. Mov Disord 2011; 26: 1825–34.
24. Harvey PO, Pruessner J, Czechowska Y, Lepage M. Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol Psychiatry 2007; 12: 767–75.
25. Heinz A, Schmidt LG, Reischies FM. Angedonia in schizophrenic, depressed, or alcohol-dependent patients-neurodiological correlates. Pharmacopsychiatry 1994; 27 (Suppl. 1): 7–10.
26. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol 2000; 247 (Suppl. 2): 110–3.
27. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 1984; 11 (Suppl. 1): 105–7.
28. Gantello R, Aguggia M, Gilli M et al. Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the “gedonic” dopamine synapse. J Neurol Neurosurg Psychiatry 1989; 52: 724–31.
29. Grafton ST. Сontributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004; 14: 715–9.
30. Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005; 111: 94–105.
31. Pizzagalli DA, Oakes TR, Fox AS et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry 2004; 9: 325–405.
32. Reichmann H, Brecht HM, Kraus PH et al. Pramipexole in Parkinson disease. Results of a treatment observation. Nervenarzt 2002; 73 (80): 745–50.
33. Isella V, Iurlano S, Pioti R et al. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 1308–11.
34. Weintraub D, Cary MS, Stern M.B et al. Daily affect in Parkinson’s disease is responsive to life events and motor symptoms. Am J Geriatr Psychiatry 2006; 14:161–8.

Н.В.Федорова, А.В.Никитина

ГОУ ДПО РМАПО Минздравсоцразвития РФ; 
Федеральный центр экстрапирамидных заболеваний нервной системы Минздравсоцразвития РФ